Markets:

Overview

News

Currencies

International

Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

8.780 -0.120 (-1.35%)

Streaming Delayed Price Updated: 1:48 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FibroGen, Inc - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

38 Stocks Moving In Friday's Mid-Day Session ↗

August 20, 2021

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021 ↗

August 20, 2021

Upgrades For Investors Bancorp Inc (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat ↗

August 20, 2021

The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...

Via Benzinga

Here's What Recent News From the FDA Means for AstraZeneca ↗

August 20, 2021

Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.

Via The Motley Fool

22 Stocks Moving in Friday's Pre-Market Session ↗

August 20, 2021

Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society...

Via Benzinga

A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings; Crude Oil Edges Lower ↗

August 20, 2021

Pre-open movers U.S. stock futures traded lower in early pre-market trade after closing mixed in the previous session. Investors are awaiting earnings results from Deere &...

Via Benzinga

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗

August 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗

August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial ↗

August 11, 2021

The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

August 10, 2021

Rosenblatt raised the price target on The Trade Desk, Inc. (NASDAQ:

Via Benzinga

FibroGen, inc (FGEN) Q2 2021 Earnings Call Transcript ↗

August 10, 2021

FGEN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

August 02, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

What's Next for FibroGen After an FDA Vote Against Its Anemia Drug? ↗

July 29, 2021

FDA approval of roxadustat seems unlikely.

Via The Motley Fool

Topics Cannabis

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies ↗

July 24, 2021

Qiming, a prominent China-based venture capital firm, has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial...

Via Talk Markets

FibroGen Out-Licenses Recombinant Human Collagen-Based Biosynthetic Cornea ↗

July 19, 2021

Eluminex Biosciences (Suzhou) Limited has exclusively licensed global rights to develop and commercialize a biosynthetic cornea from FibroGen Inc (NASDAQ:...

Via Benzinga

50 Biggest Movers From Friday ↗

July 19, 2021

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 41.2% to settle at $7.10 on Friday. Blue Foundry Bancorp (NASDAQ: BLFY) gained 29% to close at $12.90 after the...

Via Benzinga

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs ↗

July 18, 2021

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,...

Via Talk Markets

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs ↗

July 18, 2021

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Aehr Test Systems Shares Spike Higher ↗

July 16, 2021

Toward the end of trading Friday, the Dow traded down 0.63% to 34,766.06 while the NASDAQ fell 0.47% to 14,475.13. The S&P also fell, dropping 0.53% to 4,336.88. The U.S. has...

Via Benzinga

Topics Stocks

Here's Why FibroGen Stock Is Plunging Today ↗

July 16, 2021

An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.

Via The Motley Fool

Stocks Reverse Gains as Inflation Fears Weigh ↗

July 16, 2021

Stocks reversed earlier gains brought on by strong retail sales data and mixed earnings reports, as worse-than-expected inflation findings weighed on Wall Street.

Via Talk Markets

FibroGen Analyst Removes Roxadustat Sales From Model After AdCom Snub ↗

July 16, 2021

FibroGen, Inc. (NASDAQ:FGEN) shares were slumping over 40%...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.